Atossa_Therapeutics_logo-min.png
Atossa Therapeutics Adjourns Special Stockholder Meeting to October 7, 2021 to Allow Additional Time to Vote
September 07, 2021 17:20 ET | Atossa Therapeutics, Inc.
Leading proxy advisory firms ISS and Glass Lewis recommend voting in favor Atossa establishes intended criteria for non-use of additional shares for financing transactions SEATTLE, Sept. 07, 2021 ...
Atossa_Therapeutics_logo-min.png
Atossa Therapeutics Receives Approval from the Swedish Ethics Review Authority to Initiate a Phase 2 Clinical Study of Oral Endoxifen to Reduce Mammographic Breast Density in Sweden
September 02, 2021 09:30 ET | Atossa Therapeutics, Inc.
SEATTLE, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...
Atossa_Therapeutics_logo-min.png
Atossa Therapeutics Announces Second Quarter 2021 Financial Results - Provides Corporate Update and Information about Upcoming Stockholder Meeting
August 13, 2021 09:30 ET | Atossa Therapeutics, Inc.
SEATTLE, Aug. 13, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in oncology and...
Atossa_Therapeutics_logo-min.png
Atossa Therapeutics to Present at the BTIG Virtual Biotechnology Conference on August 9-10, 2021
August 05, 2021 09:30 ET | Atossa Therapeutics, Inc.
SEATTLE, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...
Atossa_Therapeutics_logo-min.png
Atossa Therapeutics Receives Regulatory Approval To Open Clinical Study of AT-H201 in Australia
July 07, 2021 09:30 ET | Atossa Therapeutics, Inc.
Nebulized formulation being developed to improve lung function in both active-disease COVID-19 patients and “Long Haul” patients with post-infection pulmonary disease SEATTLE, July 07, 2021 (GLOBE...
Atossa_Therapeutics_logo-min.png
Atossa Therapeutics Set to Be Included in the Russell 2000 and Russell 3000 Indexes
June 16, 2021 09:00 ET | Atossa Therapeutics, Inc.
SEATTLE, June 16, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...
Atossa_Therapeutics_logo-min.png
Atossa Therapeutics Receives Approval from Swedish Regulators to Initiate Phase 2 Clinical Study of Oral Endoxifen to Reduce Mammographic Breast Density
June 11, 2021 09:00 ET | Atossa Therapeutics, Inc.
SEATTLE, June 11, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in oncology and...
Atossa_Therapeutics_logo-min.png
Atossa Therapeutics Announces Final Data from Phase 2 Endoxifen Breast Cancer Study Primary Endpoint Met: 65.1% Reduction in Biomarker Ki-67; Secondary Endpoint Met: Endoxifen Safe and Well Tolerated
June 09, 2021 09:00 ET | Atossa Therapeutics, Inc.
SEATTLE, June 09, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...
Atossa_Therapeutics_logo-min.png
Atossa Therapeutics to Release Final Data from Phase 2 Study of Endoxifen Administered to Breast Cancer Patients Prior to Surgery at a Webinar at 8 am Pacific Time on June 9, 2021
June 07, 2021 09:00 ET | Atossa Therapeutics, Inc.
SEATTLE, June 07, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in oncology and...
Atossa_Therapeutics_logo-min.png
Atossa Therapeutics Announces First Quarter 2021 Financial Results and Provides Corporate Update
May 14, 2021 09:15 ET | Atossa Therapeutics, Inc.
SEATTLE, May 14, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in oncology and...